Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025 -123601.7% Operating margin3 -86.6% Revenue growth, 20253 Where the money goes Where each dollar of revenue went, fiscal 2025 Income tax
Out of $59.0K in revenue.3
Financial statements
Income statement Balance sheet Cash flow
Annual Quarterly
Revenue4 5 6 7 8 3 $59.0K in 2025−99% since 2019 0 $5.0M $10.0M $15.0M $20.0M 2019: $6.8M $6.8M 2019 2020: $6.7M $6.7M 2020 −1% 2021: $5.4M $5.4M 2021 −19% 2022: $18.1M $18.1M 2022 +234% 2023: $1.9M $1.9M 2023 −89% 2024: $441.0K $441.0K 2024 −77% 2025: $59.0K $59.0K 2025 −87% Operating income4 5 6 7 8 3 -$72.9M in 2025+352% since 2019 -$100.0M -$75.0M -$50.0M -$25.0M 0 2019: -$16.1M -$16.1M 2019 2020: -$72.8M -$72.8M 2020 +351% 2021: -$82.1M -$82.1M 2021 +13% 2022: -$37.4M -$37.4M 2022 −54% 2023: -$27.4M -$27.4M 2023 −27% 2024: -$68.5M -$68.5M 2024 +150% 2025: -$72.9M -$72.9M 2025 +6% Net income4 5 6 7 8 3 -$78.3M in 2025+387% since 2019 -$100.0M -$75.0M -$50.0M -$25.0M 0 2019: -$16.1M -$16.1M 2019 2020: -$63.5M -$63.5M 2020 +295% 2021: -$84.4M -$84.4M 2021 +33% 2022: -$41.7M -$41.7M 2022 −51% 2023: -$31.5M -$31.5M 2023 −24% 2024: -$35.1M -$35.1M 2024 +11% 2025: -$78.3M -$78.3M 2025 +123% Operating income9 10 -$31.5M in Q2 FY2026+51% since Q1 FY2026 -$40.0M -$30.0M -$20.0M -$10.0M 0 Q1 FY2026: -$20.9M -$20.9M Q1 FY2026 Q2 FY2026: -$31.5M -$31.5M Q2 FY2026 +51% Net income9 10 -$36.4M in Q2 FY2026+85% since Q1 FY2026 -$40.0M -$30.0M -$20.0M -$10.0M 0 Q1 FY2026: -$19.6M -$19.6M Q1 FY2026 Q2 FY2026: -$36.4M -$36.4M Q2 FY2026 +85% Fiscal year 2019 2020 2021 2022 2023 2024 2025 Revenue $6.8M4 $6.7M5 $5.4M6 $18.1M7 $1.9M8 $441.0K3 $59.0K3 Cost of revenue -$566.5K11 $300.0K5 $1.5M6 $3.4M7 $1.3M7 Research and development Selling, general and admin $20.7M7 $10.3M7 Operating income -$16.1M4 -$72.8M5 -$82.1M6 -$37.4M7 -$27.4M8 -$68.5M3 -$72.9M3 Income tax $280.3K4 -$2.8M5 -$196.0K6 $28.0K7 $14.0K8 $114.0K3 $165.0K3 Net income -$16.1M4 -$63.5M5 -$84.4M6 -$41.7M7 -$31.5M8 -$35.1M3 -$78.3M3 Earnings per share -$1,063.007 -$113.588 -$7.943 -$5.843 Earnings per share (diluted) -$1,063.007 -$113.588 -$20.913 -$5.843
Total assets4 5 6 7 8 3 $116.5M in 2025+223% since 2019 0 $50.0M $100.0M $150.0M $200.0M 2019: $36.1M $36.1M 2019 2020: $43.8M $43.8M 2020 +21% 2021: $80.2M $80.2M 2021 +83% 2022: $33.4M $33.4M 2022 −58% 2023: $21.0M $21.0M 2023 −37% 2024: $150.7M $150.7M 2024 +618% 2025: $116.5M $116.5M 2025 −23% Total liabilities4 5 6 7 8 3 $33.4M in 2025+121% since 2019 0 $20.0M $40.0M $60.0M 2019: $15.1M $15.1M 2019 2020: $19.2M $19.2M 2020 +27% 2021: $57.1M $57.1M 2021 +198% 2022: $44.3M $44.3M 2022 −22% 2023: $13.7M $13.7M 2023 −69% 2024: $17.7M $17.7M 2024 +29% 2025: $33.4M $33.4M 2025 +89% Shareholders’ equity5 6 7 8 3 $83.0M in 2025+296% since 2019 -$50.0M 0 $50.0M $100.0M $150.0M 2019: $21.0M $21.0M 2019 2020: $24.6M $24.6M 2020 +17% 2021: $23.1M $23.1M 2021 −6% 2022: -$10.9M -$10.9M 2022 2023: $7.3M $7.3M 2023 2024: $133.0M $133.0M 2024 +1721% 2025: $83.0M $83.0M 2025 −38% Cash4 5 6 7 8 3 $15.9M in 2025+339% since 2019 0 $50.0M $100.0M $150.0M 2019: $3.6M $3.6M 2019 2020: $18.9M $18.9M 2020 +424% 2021: $54.6M $54.6M 2021 +189% 2022: $13.2M $13.2M 2022 −76% 2023: $7.4M $7.4M 2023 −44% 2024: $134.5M $134.5M 2024 +1715% 2025: $15.9M $15.9M 2025 −88% Total assets9 10 $490.8M in Q2 FY2026+321% since Q1 FY2025 0 $200.0M $400.0M $600.0M Q1 FY2025: $116.5M $116.5M Q1 FY2025 Q2 FY2025: $116.5M $116.5M Q2 FY2025 +0% Q1 FY2026: $99.9M $99.9M Q1 FY2026 −14% Q2 FY2026: $490.8M $490.8M Q2 FY2026 +391% Total liabilities9 10 $42.1M in Q2 FY2026+26% since Q1 FY2025 0 $20.0M $40.0M $60.0M Q1 FY2025: $33.4M $33.4M Q1 FY2025 Q2 FY2025: $33.4M $33.4M Q2 FY2025 +0% Q1 FY2026: $31.6M $31.6M Q1 FY2026 −6% Q2 FY2026: $42.1M $42.1M Q2 FY2026 +33% Shareholders’ equity9 10 $448.7M in Q2 FY2026+440% since Q1 FY2025 0 $200.0M $400.0M $600.0M Q1 FY2025: $83.0M $83.0M Q1 FY2025 Q2 FY2025: $83.0M $83.0M Q2 FY2025 +0% Q1 FY2026: $68.3M $68.3M Q1 FY2026 −18% Q2 FY2026: $68.3M $68.3M Q2 FY2026 +0% Q2 FY2026: $448.7M $448.7M Q2 FY2026 +557% Cash9 10 $85.4M in Q2 FY2026+438% since Q1 FY2025 0 $25.0M $50.0M $75.0M $100.0M Q1 FY2025: $15.9M $15.9M Q1 FY2025 Q2 FY2025: $15.9M $15.9M Q2 FY2025 +0% Q1 FY2026: $25.0M $25.0M Q1 FY2026 +58% Q2 FY2026: $85.4M $85.4M Q2 FY2026 +242% Fiscal year 2019 2020 2021 2022 2023 2024 2025 Cash $3.6M4 $18.9M5 $54.6M6 $13.2M7 $7.4M8 $134.5M3 $15.9M3 Current assets $17.7M4 $26.0M5 $61.8M6 $16.4M7 $8.4M8 $138.9M3 $105.3M3 Total assets $36.1M4 $43.8M5 $80.2M6 $33.4M7 $21.0M8 $150.7M3 $116.5M3 Current liabilities $12.2M4 $15.2M5 $19.9M6 $22.1M7 $4.6M8 $7.0M3 $12.9M3 Long-term debt Total liabilities $15.1M4 $19.2M5 $57.1M6 $44.3M7 $13.7M8 $17.7M3 $33.4M3 Shareholders’ equity $21.0M5 $24.6M6 $23.1M7 -$10.9M8 $7.3M3 $133.0M3 $83.0M3 Shares outstanding 44.4M shares4 75.0M shares5 9.4M shares6 39.3K shares7 801.7K shares8 10.5M shares3 18.5M shares3
Cash from operations4 5 6 7 8 3 -$51.5M in 2025+169% since 2019 -$80.0M -$60.0M -$40.0M -$20.0M 0 2019: -$19.1M -$19.1M 2019 2020: -$40.5M -$40.5M 2020 +112% 2021: -$70.9M -$70.9M 2021 +75% 2022: -$26.8M -$26.8M 2022 −62% 2023: -$30.7M -$30.7M 2023 +15% 2024: -$49.1M -$49.1M 2024 +60% 2025: -$51.5M -$51.5M 2025 +5% Capital spending4 5 6 $95.0K in 2022−64% since 2019 0 $100.0K $200.0K $300.0K 2019: $262.0K $262.0K 2019 2020: $63.0K $63.0K 2020 −76% 2021: $113.0K $113.0K 2021 +79% 2022: $95.0K $95.0K 2022 −16% Free cash flow4 5 6 7 -$26.8M in 2022+38% since 2019 -$80.0M -$60.0M -$40.0M -$20.0M 0 2019: -$19.4M -$19.4M 2019 2020: -$40.6M -$40.6M 2020 +109% 2021: -$71.0M -$71.0M 2021 +75% 2022: -$26.8M -$26.8M 2022 −62% Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Fiscal year 2019 2020 2021 2022 2023 2024 2025 Cash from operations -$19.1M4 -$40.5M5 -$70.9M6 -$26.8M7 -$30.7M8 -$49.1M3 -$51.5M3 Capital spending $262.0K4 $63.0K5 $113.0K6 $95.0K6 Free cash flow -$19.4M -$40.6M -$71.0M -$26.8M
Compare Avalo Therapeutics, Inc. with another company
Former names
Cerecor Inc. Apr 4, 2012 to Aug 18, 20212
Recent filings
Oct 2, 2026 4 Oct 2, 2026 4 Oct 2, 2026 4 Sep 18, 2026 4 Sep 11, 2026 4 Sep 1, 2026 4 Aug 19, 2026 4 Aug 19, 2026 4 Aug 18, 2026 144 Aug 17, 2026 144 Aug 17, 2026 144 Aug 17, 2026 144 Aug 14, 2026 SCHEDULE 13G/A Aug 14, 2026 SCHEDULE 13G/A Aug 14, 2026 SCHEDULE 13G/A Every filing from the last three years, summarized . The full record is on SEC EDGAR.1
